The JAK2 V617F mutation in Philadelphia-negative chronic myeloproliferative disorders
نویسندگان
چکیده
منابع مشابه
Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The hematopoietic progenitor cells of patients with polycythemia vera (PV) or essential thrombocythemia (ET) are characterized by hypersensitivity to hematopoietic growth factors and formation of endogenous erythroid colonies. Recently, 4 groups reported almost simultaneously Janus kinase 2 (JAK2) V6...
متن کاملLeukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-negative AML. Microsat...
متن کاملjak2-v617f mutation and philadelphia positive chronic myeloid leukemia
jak2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. a single acquired point mutation – v617f – in jak2 occurs in the great majority of patients with polycythemia vera (pv) and approximately half of the patients with idiopathic myelofibrosis (imf) or essential thrombocythemia (et). in contrast, the jak2-v617f mutation is...
متن کاملJAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
JAK2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. A single acquired point mutation – V617F – in JAK2 occurs in the great majority of patients with polycythemia vera (PV) and approximately half of the patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET). In contrast, the JAK2-V617F mutation is...
متن کاملDiagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
In 2005, multiple groups identified a high frequency of the V617F (G→T) mutation in the tyrosine kinase gene JAK2 as the most common molecular abnormality in chronic myeloproliferative disorders. Before 2005, there had been no recurring cytogenetic abnormality described at a high incidence in these disorders. The initial descriptions could well be classified as discovery papers because each gro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Pathology
سال: 2006
ISSN: 0021-9746
DOI: 10.1136/jcp.2006.044644